The increasing prevalence of the lung cancer among the population fuels the global PD-1 and PD-L1 inhibitors market growth. The Global PD-1 and PD-L1 Inhibitors Market was valued at USD 33.1 billion in 2020, and it is expected to reach USD 117.2 billion by 2027, with a CAGR of 19.8% during the forecast period.
The major driving factors of the PD-1 and PD-L1 inhibitors market growth includes rising prevalence of non-small cell lung cancer due to change in lifestyle in the developed and developing regions. The adoption of PD-1 and PD-L1 inhibitors proves as a more efficient treatment for the solid tumours and blood related tumour cancer which is considerably driving factors influencing the growth of the global PD-1 and PD-L1 market. For example, according to statics given by ThermoFisher Scientific among all types of the cancer solid tumours holds over 40% of share.
The PD-1 and PD-L1 inhibitors are used as first line treatment for the cancer. It is used before chemotherapy to treat the cancer. However, these are the boosting factors for the growth of global PD-1 and PD-L1 inhibitors market. Increasing investment in R&D sector of PD-1 and PD-L1 inhibitors drug development creates tremendous opportunity for the growth of PD-1 and PD-L1 inhibitors market. Further, the increasing number of PD-1 and PD-L1 inhibitors drugs in the pipeline is considerably the major opportunity to positively drive the global PD-1 and PD-L1 inhibitors market.
However, the high cost of PD-1 and PD-L1 inhibitors drugs is the restraining factor for the growth of the PD-1 and PD-L1 inhibitors market. Additionally, the safety concern and side effects of the drug hinders the growth of global PD-1 and PD-L1 inhibitors market.
Global PD-1 and PD-L1 Inhibitors Market by Application Outlook (Revenue, USD Billion, 2021-2027)
In the application segment, the solid tumours segment is the fastest growing sub segment and are followed by the tumours related to blood for PD-1 and PD-L1 inhibitors market. Solid tumour includes the sarcomas, lymphomas, and carcinomas whereas tumours related to blood includes myeloma, lymphoma, and leukemia. The increasing patient pool of various cancer such as lung cancer, bone cancer, breast cancer, colon cancer and others including solid tumors is considerably driving the growth of solid tumors sub-segment.
The Global PD-1 and PD-L1 Inhibitors Market Segmentation:
Global PD-1 and PD-L1 Inhibitors Market by Type Outlook (Revenue, USD Billion, 2021-2027)
Global PD-1 and PD-L1 Inhibitors Market by Region Outlook (Revenue, USD Billion, 2021-2027)
Key Findings:
Company Profiles and Competitive Intelligence
The key players operating in the global PD-1 and PD-L1 inhibitors market are:
Recent News:
Log in / Register